Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Keith L. Ligon, MD, PhD


Pathology

No Ratings Available - Why Not? Make an Appointment

Physician

  • Chief, Division of Neuropathology, Brigham and Women’s Hospital
  • Director, Center for Patient Derived Models, Dana-Farber Cancer Institute
  • Associate Professor of Pathology, Harvard Medical School

Clinical Interests

  • Developmental neuropathology
  • General neuropathology
  • Neuropathology of brain tumors

Diseases Treated

  • Brain Metastasis
  • Brain Tumors
  • Glioblastoma
  • Low-Grade Glioma
  • Lymphoma, Primary CNS
  • Meningioma
  • AT/RT, Childhood
  • Brain Tumors, Childhood
  • Choroid Plexus Tumor, Childhood
  • DIPG, Childhood
  • Ependymoma, Childhood
  • Germ Cell Tumors of the Brain, Childhood
  • Glioma, Childhood
  • Medulloblastoma, Childhood

Contact Information

  • Office Phone Number617-632-2357
  • Fax617-632-8761

Bio

Dr. Ligon is a Physician-Scientist with expertise in neuropathology and oncology focused on improving the diagnosis and treatment of cancer. He attended medical school and received his PhD at the University of Texas-Houston Medical School and the M.D. Anderson Cancer Center. Currently he is an Associate Professor of Pathology at Harvard Medical School with joint appointments at the Dana-Farber Cancer Institute, the Broad Institute, and Brigham and Women’s Hospital (BWH). He is the Chief of Neuropathology at BWH/DFCI and the Director of the Center for Patient Derived Models (CPDM) at DFCI. His research and clinical activities have improved the scientific understanding of brain tumors. He is directly involved in the training of medical and graduate students, postdoctoral fellows, residents, and faculty. Several of the methods he has developed in his research have been implemented in the clinical pathology lab to improve patient diagnosis. He has also led efforts to train neuropathologists in the utilization of genomic tests in practice and led genomically informed clinical trials development at the local and national consortium levels.

Board Certification:

  • Anatomic Pathology, 2001
  • Neuropathology, 2001

Fellowship:

  • Brigham and Women's Hospital, Neuropathology

Residency:

  • Brigham and Women's Hospital, Anatomic Pathology

Medical School:

  • University of Texas Medical School at Houston

Research

The focus of my work is on the basic and translational investigation of brain tumors. We specifically study developmental transcription factors and their role in brain tumor formation and neural stem cell biology. Translational studies in the lab utilize genomics and pathology tools to study human tumors. Our lab has expertise in adult and pediatric gliomas and specifically our work has focused on use of human patient derived cell line and patient derived xenograft models (PDCL, PDX), mouse genetic models (GEMMs). We also have extensive collaborations around human clinical trials for brain tumors and development of biomarkers to improve outcomes of brain tumor patients.

Quantification of aneuploidy in targeted sequencing data using ASCETS. Bioinformatics. 2021 Aug 25; 37(16):2461-2463.
View in: PubMed

Rates and patterns of clonal oncogenic mutations in the normal human brain. Cancer Discov. 2021 Aug 13.
View in: PubMed

Multimodal platform for assessing drug distribution and response in clinical trials. Neuro Oncol. 2021 Aug 12.
View in: PubMed

Prognostication for meningiomas: H3K27me3 to the rescue? Neuro Oncol. 2021 08 02; 23(8):1218-1219.
View in: PubMed

Effect of PIK3CA variants on glioma-related epilepsy and response to treatment. Epilepsy Res. 2021 Sep; 175:106681.
View in: PubMed

Activity of PD-1 blockade with Nivolumab among patients with recurrent atypical/anaplastic meningioma: Phase II trial results. Neuro Oncol. 2021 May 20.
View in: PubMed

IDH-mutant gliomas with additional class-defining molecular events. Mod Pathol. 2021 Jul; 34(7):1236-1244.
View in: PubMed

Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis. Cell. 2021 03 04; 184(5):1281-1298.e26.
View in: PubMed

Targeting glioblastoma using a novel peptide specific to a deglycosylated isoform of brevican. Adv Ther (Weinh). 2021 Apr; 4(4).
View in: PubMed

Socioeconomic Disparities Associated With MGMT Promoter Methylation Testing for Patients With Glioblastoma. JAMA Oncol. 2020 12 01; 6(12):1972-1974.
View in: PubMed

Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis. Cell. 2020 12 10; 183(6):1617-1633.e22.
View in: PubMed

Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma. Clin Cancer Res. 2021 01 01; 27(1):276-287.
View in: PubMed

Loss of histone H3 trimethylation on lysine 27 and nuclear expression of transducin-like enhancer 1 in primary intracranial sarcoma, DICER1-mutant. Histopathology. 2021 Jan; 78(2):265-275.
View in: PubMed

Subependymal giant cell astrocytomas are characterized by mTORC1 hyperactivation, a very low somatic mutation rate, and a unique gene expression profile. Mod Pathol. 2021 02; 34(2):264-279.
View in: PubMed

Divergent Roles of PI3K Isoforms in PTEN-Deficient Glioblastomas. Cell Rep. 2020 09 29; 32(13):108196.
View in: PubMed

Epigenomic programming in early fetal brain development. Epigenomics. 2020 06; 12(12):1053-1070.
View in: PubMed

Molecular and clinicopathologic features of gliomas harboring NTRK fusions. Acta Neuropathol Commun. 2020 07 14; 8(1):107.
View in: PubMed

Single-Cell RNA-Seq Reveals Cellular Hierarchies and Impaired Developmental Trajectories in Pediatric Ependymoma. Cancer Cell. 2020 07 13; 38(1):44-59.e9.
View in: PubMed

Tumor Interferon Signaling Is Regulated by a lncRNA INCR1 Transcribed from the PD-L1 Locus. Mol Cell. 2020 06 18; 78(6):1207-1223.e8.
View in: PubMed

Prediction of Outcomes with a Computational Biology Model in Newly Diagnosed Glioblastoma Patients Treated with Radiation Therapy and Temozolomide. Int J Radiat Oncol Biol Phys. 2020 11 01; 108(3):716-724.
View in: PubMed

MR Imaging Correlates for Molecular and Mutational Analyses in Children with Diffuse Intrinsic Pontine Glioma. AJNR Am J Neuroradiol. 2020 05; 41(5):874-881.
View in: PubMed

Mechanisms and therapeutic implications of hypermutation in gliomas. Nature. 2020 04; 580(7804):517-523.
View in: PubMed

WNT-Activated Medulloblastomas With Hybrid Molecular Subtypes. JCO Precis Oncol. 2020; 4.
View in: PubMed

Correction: BPTF regulates growth of adult and pediatric high-grade glioma through the MYC pathway. Oncogene. 2020 Mar; 39(12):2641.
View in: PubMed

Early TP53 alterations engage environmental exposures to promote gastric premalignancy in an integrative mouse model. Nat Genet. 2020 02; 52(2):219-230.
View in: PubMed

The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. Neuro Oncol. 2019 12 17; 21(12):1498-1508.
View in: PubMed

A large peptidome dataset improves HLA class I epitope prediction across most of the human population. Nat Biotechnol. 2020 02; 38(2):199-209.
View in: PubMed

BPTF regulates growth of adult and pediatric high-grade glioma through the MYC pathway. Oncogene. 2020 03; 39(11):2305-2327.
View in: PubMed

Implementing Patient-Derived Xenografts to Assess the Effectiveness of Cyclin-Dependent Kinase Inhibitors in Glioblastoma. Cancers (Basel). 2019 Dec 12; 11(12).
View in: PubMed

Longitudinal molecular trajectories of diffuse glioma in adults. Nature. 2019 12; 576(7785):112-120.
View in: PubMed

Increasing value of autopsies in patients with brain tumors in the molecular era. J Neurooncol. 2019 Nov; 145(2):349-355.
View in: PubMed

Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course. Acta Neuropathol. 2020 01; 139(1):193-209.
View in: PubMed

Pineal apoplexy due to pleomorphic variant pineocytoma. Clin Neuropathol. 2019 Sep/Oct; 38(5):253-255.
View in: PubMed

Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma. Cancer Med. 2019 10; 8(13):5988-5994.
View in: PubMed

Mitogenic and progenitor gene programmes in single pilocytic astrocytoma cells. Nat Commun. 2019 08 19; 10(1):3731.
View in: PubMed

Tie2-FGFR1 Interaction Induces Adaptive PI3K Inhibitor Resistance by Upregulating Aurora A/PLK1/CDK1 Signaling in Glioblastoma. Cancer Res. 2019 10 01; 79(19):5088-5101.
View in: PubMed

Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial. Sci Transl Med. 2019 08 14; 11(505).
View in: PubMed

Molecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendations. Neuro Oncol. 2019 08 05; 21(8):968-980.
View in: PubMed

Resolving medulloblastoma cellular architecture by single-cell genomics. Nature. 2019 08; 572(7767):74-79.
View in: PubMed

An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. Cell. 2019 08 08; 178(4):835-849.e21.
View in: PubMed

Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma. Nat Commun. 2019 06 03; 10(1):2400.
View in: PubMed

Clinical Importance of CDKN2A Loss and Monosomy 10 in Pilocytic Astrocytoma. Cureus. 2019 May 23; 11(5):e4726.
View in: PubMed

Recurrent EP300-BCOR Fusions in Pediatric Gliomas With Distinct Clinicopathologic Features. J Neuropathol Exp Neurol. 2019 04 01; 78(4):305-314.
View in: PubMed

Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma. JCO Precis Oncol. 2019; 3.
View in: PubMed

CHD4 regulates the DNA damage response and RAD51 expression in glioblastoma. Sci Rep. 2019 03 14; 9(1):4444.
View in: PubMed

Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition. Elife. 2019 03 12; 8.
View in: PubMed

Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. J Clin Oncol. 2019 03 20; 37(9):741-750.
View in: PubMed

The functional synergism of microRNA clustering provides therapeutically relevant epigenetic interference in glioblastoma. Nat Commun. 2019 01 25; 10(1):442.
View in: PubMed

Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2019 01; 565(7738):234-239.
View in: PubMed

miR-4516 predicts poor prognosis and functions as a novel oncogene via targeting PTPN14 in human glioblastoma. Oncogene. 2019 04; 38(16):2923-2936.
View in: PubMed

Mismatch repair deficiency in high-grade meningioma: a rare but recurrent event associated with dramatic immune activation and clinical response to PD-1 blockade. JCO Precis Oncol. 2018; 2018.
View in: PubMed

Linking single-cell measurements of mass, growth rate, and gene expression. Genome Biol. 2018 11 27; 19(1):207.
View in: PubMed

Microfluidic active loading of single cells enables analysis of complex clinical specimens. Nat Commun. 2018 11 14; 9(1):4784.
View in: PubMed

The secreted glycolytic enzyme GPI/AMF stimulates glioblastoma cell migration and invasion in an autocrine fashion but can have anti-proliferative effects. Neuro Oncol. 2018 11 12; 20(12):1594-1605.
View in: PubMed

Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma. Neuro Oncol. 2018 10 09; 20(11):1547-1555.
View in: PubMed

Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma. Cell. 2018 09 20; 175(1):101-116.e25.
View in: PubMed

Correction to: DNA methylation-based reclassification of olfactory neuroblastoma. Acta Neuropathol. 2018 09; 136(3):505.
View in: PubMed

Vemurafenib and cobimetinib overcome resistance to vemurafenib in BRAF-mutant ganglioglioma. Neurology. 2018 09 11; 91(11):523-525.
View in: PubMed

A PDGFRa-driven mouse model of glioblastoma reveals a stathmin1-mediated mechanism of sensitivity to vinblastine. Nat Commun. 2018 08 06; 9(1):3116.
View in: PubMed

The FDA NIH Biomarkers, EndpointS, and other Tools (BEST) resource in neuro-oncology. Neuro Oncol. 2018 08 02; 20(9):1162-1172.
View in: PubMed

Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. Neuro Oncol. 2018 08 02; 20(9):1240-1250.
View in: PubMed

Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort. Cancer Immunol Res. 2018 09; 6(9):1039-1045.
View in: PubMed

Dual HDAC and PI3K Inhibition Abrogates NF?B- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas. Cancer Res. 2018 07 15; 78(14):4007-4021.
View in: PubMed

DNA methylation-based reclassification of olfactory neuroblastoma. Acta Neuropathol. 2018 08; 136(2):255-271.
View in: PubMed

Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. Science. 2018 04 20; 360(6386):331-335.
View in: PubMed

Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. Neuro Oncol. 2018 04 09; 20(5):674-686.
View in: PubMed

Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02. Neuro Oncol. 2018 03 27; 20(4):546-556.
View in: PubMed

Immunophenotyping of pediatric brain tumors: correlating immune infiltrate with histology, mutational load, and survival and assessing clonal T cell response. J Neurooncol. 2018 Apr; 137(2):269-278.
View in: PubMed

Residual Convolutional Neural Network for the Determination of IDH Status in Low- and High-Grade Gliomas from MR Imaging. Clin Cancer Res. 2018 03 01; 24(5):1073-1081.
View in: PubMed

A novel GIT2-BRAF fusion in pilocytic astrocytoma. Diagn Pathol. 2017 Nov 15; 12(1):82.
View in: PubMed

Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma. Clin Cancer Res. 2018 01 15; 24(2):295-305.
View in: PubMed

Salvage re-irradiation for recurrent high-grade glioma and comparison to bevacizumab alone. J Neurooncol. 2017 Dec; 135(3):581-591.
View in: PubMed

Nuclear CRX and FOXJ1 Expression Differentiates Non-Germ Cell Pineal Region Tumors and Supports the Ependymal Differentiation of Papillary Tumor of the Pineal Region. Am J Surg Pathol. 2017 Oct; 41(10):1410-1421.
View in: PubMed

Brainstem angiocentric gliomas with MYB-QKI rearrangements. Acta Neuropathol. 2017 Oct; 134(4):667-669.
View in: PubMed

Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. J Clin Oncol. 2017 Sep 01; 35(25):2934-2941.
View in: PubMed

Glioblastoma targeted therapy: updated approaches from recent biological insights. Ann Oncol. 2017 Jul 01; 28(7):1457-1472.
View in: PubMed

Clinical Identification of Oncogenic Drivers and Copy-Number Alterations in Pituitary Tumors. Endocrinology. 2017 07 01; 158(7):2284-2291.
View in: PubMed

Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma. Neuro Oncol. 2017 Jul 01; 19(7):908-917.
View in: PubMed

Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors. Neuro Oncol. 2017 Jul 01; 19(7):986-996.
View in: PubMed

Post-translational Modifications of OLIG2 Regulate Glioma Invasion through the TGF-ß Pathway. Cell Rep. 2017 06 13; 19(11):2410-2412.
View in: PubMed

Pediatric low-grade gliomas: implications of the biologic era. Neuro Oncol. 2017 06 01; 19(6):750-761.
View in: PubMed

A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas. Neuro Oncol. 2017 06 01; 19(6):774-785.
View in: PubMed

Intracranial myxoid mesenchymal tumors with EWSR1-CREB family gene fusions: myxoid variant of angiomatoid fibrous histiocytoma or novel entity? Brain Pathol. 2018 03; 28(2):183-191.
View in: PubMed

Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro Oncol. 2017 04 01; 19(4):535-545.
View in: PubMed

A Sequentially Priming Phosphorylation Cascade Activates the Gliomagenic Transcription Factor Olig2. Cell Rep. 2017 03 28; 18(13):3167-3177.
View in: PubMed

Nuclear inclusion bodies of mutant and wild-type p53 in cancer: a hallmark of p53 inactivation and proteostasis remodelling by p53 aggregation. J Pathol. 2017 05; 242(1):24-38.
View in: PubMed

G1 cyclins link proliferation, pluripotency and differentiation of embryonic stem cells. Nat Cell Biol. 2017 03; 19(3):177-188.
View in: PubMed

Multi-omics analysis of primary glioblastoma cell lines shows recapitulation of pivotal molecular features of parental tumors. Neuro Oncol. 2017 02 01; 19(2):219-228.
View in: PubMed

Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate. Nat Biotechnol. 2016 Nov; 34(11):1161-1167.
View in: PubMed

Tyrosine receptor kinase B is a drug target in astrocytomas. Neuro Oncol. 2017 01; 19(1):22-30.
View in: PubMed

Post-translational Modifications of OLIG2 Regulate Glioma Invasion through the TGF-ß Pathway. Cell Rep. 2016 07 26; 16(4):950-966.
View in: PubMed

Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas. Neuro Oncol. 2017 01; 19(1):109-117.
View in: PubMed

Glioproliferative Lesion of the Spinal Cord as a Complication of "Stem-Cell Tourism". N Engl J Med. 2016 Jul 14; 375(2):196-8.
View in: PubMed

Genomic characterization of recurrent high-grade astroblastoma. Cancer Genet. 2016 Jul-Aug; 209(7-8):321-30.
View in: PubMed

MAPK activation and HRAS mutation identified in pituitary spindle cell oncocytoma. Oncotarget. 2016 Jun 14; 7(24):37054-37063.
View in: PubMed

Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. Nat Med. 2016 07; 22(7):723-6.
View in: PubMed

Control of glioblastoma tumorigenesis by feed-forward cytokine signaling. Nat Neurosci. 2016 06; 19(6):798-806.
View in: PubMed

Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma. Nat Commun. 2016 Apr 06; 7:11185.
View in: PubMed

Disseminated glioneuronal tumors occurring in childhood: treatment outcomes and BRAF alterations including V600E mutation. J Neurooncol. 2016 06; 128(2):293-302.
View in: PubMed

Decreased FOXJ1 expression and its ciliogenesis programme in aggressive ependymoma and choroid plexus tumours. J Pathol. 2016 Mar; 238(4):584-97.
View in: PubMed

MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. Nat Genet. 2016 Mar; 48(3):273-82.
View in: PubMed

Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. Neuro Oncol. 2016 05; 18(5):649-55.
View in: PubMed

Case Report: Next generation sequencing identifies a NAB2-STAT6 fusion in Glioblastoma. Diagn Pathol. 2016 Jan 27; 11:13.
View in: PubMed

Myxopapillary ependymomas in children: imaging, treatment and outcomes. J Neurooncol. 2016 Jan; 126(1):165-174.
View in: PubMed

Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood. 2016 Feb 18; 127(7):869-81.
View in: PubMed

A Brain Tumor/Organotypic Slice Co-culture System for Studying Tumor Microenvironment and Targeted Drug Therapies. J Vis Exp. 2015 Nov 07; (105):e53304.
View in: PubMed

Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model. Cancer Immunol Res. 2016 Feb; 4(2):124-35.
View in: PubMed

Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas. Clin Cancer Res. 2016 Mar 01; 22(5):1185-96.
View in: PubMed

Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro Oncol. 2016 Apr; 18(4):557-64.
View in: PubMed

Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov. 2015 Nov; 5(11):1164-1177.
View in: PubMed

Somatic mutations associated with MRI-derived volumetric features in glioblastoma. Neuroradiology. 2015 Dec; 57(12):1227-37.
View in: PubMed

A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma. Neuro Oncol. 2016 Feb; 18(2):269-74.
View in: PubMed

Rapid Intraoperative Molecular Characterization of Glioma. JAMA Oncol. 2015 Aug; 1(5):662-7.
View in: PubMed

Integrated Genomic Characterization of a Pineal Parenchymal Tumor of Intermediate Differentiation. World Neurosurg. 2016 Jan; 85:96-105.
View in: PubMed

One size should not fit all: advancing toward personalized glioblastoma therapy. Discov Med. 2015 Jun; 19(107):471-7.
View in: PubMed

Toward precision medicine in glioblastoma: the promise and the challenges. Neuro Oncol. 2015 Aug; 17(8):1051-63.
View in: PubMed

A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. Clin Cancer Res. 2015 Aug 15; 21(16):3610-8.
View in: PubMed

Calibrating genomic and allelic coverage bias in single-cell sequencing. Nat Commun. 2015 Apr 16; 6:6822.
View in: PubMed

SHMT2 drives glioma cell survival in ischaemia but imposes a dependence on glycine clearance. Nature. 2015 Apr 16; 520(7547):363-7.
View in: PubMed

Hypofractionated versus standard radiation therapy with or without temozolomide for older glioblastoma patients. Int J Radiat Oncol Biol Phys. 2015 Jun 01; 92(2):384-9.
View in: PubMed

Expression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtype. Neuro Oncol. 2015 Nov; 17(11):1486-96.
View in: PubMed

Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. Oncotarget. 2015 Mar 10; 6(7):4704-16.
View in: PubMed

Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. Neuro Oncol. 2015 Oct; 17(10):1344-55.
View in: PubMed

Intermediate DNA methylation is a conserved signature of genome regulation. Nat Commun. 2015 Feb 18; 6:6363.
View in: PubMed

BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. J Clin Oncol. 2015 Mar 20; 33(9):1015-22.
View in: PubMed

Temozolomide resistance in glioblastoma occurs by miRNA-9-targeted PTCH1, independent of sonic hedgehog level. Oncotarget. 2015 Jan 20; 6(2):1190-201.
View in: PubMed

Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. Neuro Oncol. 2015 Jun; 17(6):862-7.
View in: PubMed

Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. Neurology. 2015 Jan 20; 84(3):280-6.
View in: PubMed

A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K. Neuro Oncol. 2015 Sep; 17(9):1261-9.
View in: PubMed

A five-gene hedgehog signature developed as a patient preselection tool for hedgehog inhibitor therapy in medulloblastoma. Clin Cancer Res. 2015 Feb 01; 21(3):585-93.
View in: PubMed

Angiomatous meningiomas have a distinct genetic profile with multiple chromosomal polysomies including polysomy of chromosome 5. Oncotarget. 2014 Nov 15; 5(21):10596-606.
View in: PubMed

Interrogation of gossypol therapy in glioblastoma implementing cell line and patient-derived tumour models. Br J Cancer. 2014 Dec 09; 111(12):2275-86.
View in: PubMed

Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma. Neuro Oncol. 2015 May; 17(5):697-707.
View in: PubMed

Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas. J Neurooncol. 2015 Jan; 121(2):297-302.
View in: PubMed

Molecular pathologic diagnosis of epidermal growth factor receptor. Neuro Oncol. 2014 Oct; 16 Suppl 8:viii1-6.
View in: PubMed

Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas. Oncotarget. 2014 Sep 30; 5(18):8083-92.
View in: PubMed

Specific detection of methionine 27 mutation in histone 3 variants (H3K27M) in fixed tissue from high-grade astrocytomas. Acta Neuropathol. 2014 Nov; 128(5):733-41.
View in: PubMed

Prominin-1 (CD133) defines both stem and non-stem cell populations in CNS development and gliomas. PLoS One. 2014; 9(9):e106694.
View in: PubMed

Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group. Neuro Oncol. 2015 Feb; 17(2):180-8.
View in: PubMed

Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol. 2015 Jan; 17(1):116-21.
View in: PubMed

Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors. Neuro Oncol. 2014 Nov; 16(11):1541-6.
View in: PubMed

Immune checkpoint blockade for glioblastoma: preclinical activity of single agent and combinatorial therapy. Neuro Oncol. 2014 Jul; 16 Suppl 3:iii11-iii12.
View in: PubMed

Phase ii trial of the phosphatidyinositol-3 kinase (pi3k) inhibitor buparlisib (bkm120) in recurrent glioblastoma conducted by the ivy foundation early phase clinical trials consortium. Neuro Oncol. 2014 Jul; 16 Suppl 3:iii47.
View in: PubMed

Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain tumor surgery. Proc Natl Acad Sci U S A. 2014 Jul 29; 111(30):11121-6.
View in: PubMed

EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing. Cancer Discov. 2014 Aug; 4(8):956-71.
View in: PubMed

Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. Nat Genet. 2014 May; 46(5):462-6.
View in: PubMed

Temozolomide resistance in glioblastoma cells occurs partly through epidermal growth factor receptor-mediated induction of connexin 43. Cell Death Dis. 2014 Mar 27; 5:e1145.
View in: PubMed

Tumor associated seizures in glioblastomas are influenced by survival gene expression in a region-specific manner: a gene expression imaging study. Epilepsy Res. 2014 Jul; 108(5):843-52.
View in: PubMed

SOX2 and p63 colocalize at genetic loci in squamous cell carcinomas. J Clin Invest. 2014 Apr; 124(4):1636-45.
View in: PubMed

D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. Genes Dev. 2014 Mar 01; 28(5):479-90.
View in: PubMed

Pediatric low-grade gliomas: how modern biology reshapes the clinical field. Biochim Biophys Acta. 2014 Apr; 1845(2):294-307.
View in: PubMed

Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Neuro Oncol. 2014 Apr; 16(4):567-78.
View in: PubMed

ZFHX4 interacts with the NuRD core member CHD4 and regulates the glioblastoma tumor-initiating cell state. Cell Rep. 2014 Jan 30; 6(2):313-24.
View in: PubMed

Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet. 2014 Feb; 46(2):161-5.
View in: PubMed

Pten loss in Olig2 expressing neural progenitor cells and oligodendrocytes leads to interneuron dysplasia and leukodystrophy. Stem Cells. 2014 Jan; 32(1):313-26.
View in: PubMed

Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncol. 2013 Nov; 14(12):1200-7.
View in: PubMed

Delivery of Functional Anti-miR-9 by Mesenchymal Stem Cell-derived Exosomes to Glioblastoma Multiforme Cells Conferred Chemosensitivity. Mol Ther Nucleic Acids. 2013 Oct 01; 2:e126.
View in: PubMed

Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities. Nat Med. 2013 Nov; 19(11):1518-23.
View in: PubMed

Rapid, label-free detection of brain tumors with stimulated Raman scattering microscopy. Sci Transl Med. 2013 Sep 04; 5(201):201ra119.
View in: PubMed

Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet. 2013 Aug; 45(8):927-32.
View in: PubMed

Estimating absolute methylation levels at single-CpG resolution from methylation enrichment and restriction enzyme sequencing methods. Genome Res. 2013 Sep; 23(9):1541-53.
View in: PubMed

Functional DNA methylation differences between tissues, cell types, and across individuals discovered using the M&M algorithm. Genome Res. 2013 Sep; 23(9):1522-40.
View in: PubMed

DNA hypomethylation within specific transposable element families associates with tissue-specific enhancer landscape. Nat Genet. 2013 Jul; 45(7):836-41.
View in: PubMed

Enhancing radiation therapy for patients with glioblastoma. Expert Rev Anticancer Ther. 2013 May; 13(5):569-81.
View in: PubMed

Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. Proc Natl Acad Sci U S A. 2013 May 14; 110(20):8188-93.
View in: PubMed

Phase 2 study of dose-intense temozolomide in recurrent glioblastoma. Neuro Oncol. 2013 Jul; 15(7):930-5.
View in: PubMed

PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma. Brain Pathol. 2013 Sep; 23(5):565-73.
View in: PubMed

Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet. 2013 Mar; 45(3):285-9.
View in: PubMed

Ambient mass spectrometry for the intraoperative molecular diagnosis of human brain tumors. Proc Natl Acad Sci U S A. 2013 Jan 29; 110(5):1611-6.
View in: PubMed

Somatic mutations of PIK3R1 promote gliomagenesis. PLoS One. 2012; 7(11):e49466.
View in: PubMed

Integrative functional genomics identifies RINT1 as a novel GBM oncogene. Neuro Oncol. 2012 Nov; 14(11):1325-31.
View in: PubMed

Absence of oncogenic canonical pathway mutations in aggressive pediatric rhabdoid tumors. Pediatr Blood Cancer. 2012 Dec 15; 59(7):1155-7.
View in: PubMed

Brain and testicular tumors in mice with progenitor cells lacking BAX and BAK. Oncogene. 2013 Aug 29; 32(35):4078-85.
View in: PubMed

BRAF duplications and MAPK pathway activation are frequent in gliomas of the optic nerve proper. J Neuropathol Exp Neurol. 2012 Sep; 71(9):789-94.
View in: PubMed

Prospective, high-throughput molecular profiling of human gliomas. J Neurooncol. 2012 Oct; 110(1):89-98.
View in: PubMed

Zebrafish neurofibromatosis type 1 genes have redundant functions in tumorigenesis and embryonic development. Dis Model Mech. 2012 Nov; 5(6):881-94.
View in: PubMed

DNA fragmentation simulation method (FSM) and fragment size matching improve aCGH performance of FFPE tissues. PLoS One. 2012; 7(6):e38881.
View in: PubMed

Initial treatment patterns over time for anaplastic oligodendroglial tumors. Neuro Oncol. 2012 Jun; 14(6):761-7.
View in: PubMed

Current clinical development of PI3K pathway inhibitors in glioblastoma. Neuro Oncol. 2012 Jul; 14(7):819-29.
View in: PubMed

Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev. 2012 Apr 15; 26(8):756-84.
View in: PubMed

Somatic activation of AKT3 causes hemispheric developmental brain malformations. Neuron. 2012 Apr 12; 74(1):41-8.
View in: PubMed

Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature. 2012 Feb 15; 483(7390):484-8.
View in: PubMed

Neoplastic cells are a rare component in human glioblastoma microvasculature. Oncotarget. 2012 Jan; 3(1):98-106.
View in: PubMed

Classifying human brain tumors by lipid imaging with mass spectrometry. Cancer Res. 2012 Feb 01; 72(3):645-54.
View in: PubMed

Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas. J Mol Diagn. 2011 Nov; 13(6):669-77.
View in: PubMed

Maintenance of tumor initiating cells of defined genetic composition by nucleostemin. Proc Natl Acad Sci U S A. 2011 Dec 20; 108(51):20388-93.
View in: PubMed

International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro Oncol. 2011 Jun; 13(6):649-59.
View in: PubMed

Human glioma growth is controlled by microRNA-10b. Cancer Res. 2011 May 15; 71(10):3563-72.
View in: PubMed

BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One. 2011 Mar 29; 6(3):e17948.
View in: PubMed

The central nervous system-restricted transcription factor Olig2 opposes p53 responses to genotoxic damage in neural progenitors and malignant glioma. Cancer Cell. 2011 Mar 08; 19(3):359-71.
View in: PubMed

Glioma models: new GEMMs add "class" with genomic and expression correlations. Cancer Cell. 2011 Mar 08; 19(3):295-7.
View in: PubMed

Development of stereotactic mass spectrometry for brain tumor surgery. Neurosurgery. 2011 Feb; 68(2):280-89; discussion 290.
View in: PubMed

Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol. 2011 Apr 10; 29(11):1424-30.
View in: PubMed

Discrimination of human astrocytoma subtypes by lipid analysis using desorption electrospray ionization imaging mass spectrometry. Angew Chem Int Ed Engl. 2010 Aug 09; 49(34):5953-6.
View in: PubMed

Epidermal growth factor receptor gene amplification in atypical adenomatous hyperplasia of the lung. Am J Transl Res. 2010 May 16; 2(3):309-15.
View in: PubMed

Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys. 2010 Sep 01; 78(1):85-90.
View in: PubMed

Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence. Proc Natl Acad Sci U S A. 2010 Feb 09; 107(6):2616-21.
View in: PubMed

Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro Oncol. 2009 Dec; 11(6):853-60.
View in: PubMed

CRX is a diagnostic marker of retinal and pineal lineage tumors. PLoS One. 2009 Nov 20; 4(11):e7932.
View in: PubMed

Profiling critical cancer gene mutations in clinical tumor samples. PLoS One. 2009 Nov 18; 4(11):e7887.
View in: PubMed

FoxOs cooperatively regulate diverse pathways governing neural stem cell homeostasis. Cell Stem Cell. 2009 Nov 06; 5(5):540-53.
View in: PubMed

Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss. Clin Cancer Res. 2009 Oct 15; 15(20):6430-7.
View in: PubMed

Myelin gene regulatory factor is a critical transcriptional regulator required for CNS myelination. Cell. 2009 Jul 10; 138(1):172-85.
View in: PubMed

Array-based genomics in glioma research. Brain Pathol. 2010 Jan; 20(1):28-38.
View in: PubMed

Pten and p53 converge on c-Myc to control differentiation, self-renewal, and transformation of normal and neoplastic stem cells in glioblastoma. Cold Spring Harb Symp Quant Biol. 2008; 73:427-37.
View in: PubMed

A novel TP53 germline mutation in a family with a history of multiple malignancies: case report and review of the literature. Pediatr Neurosurg. 2008; 44(6):501-8.
View in: PubMed

Meningioangiomatosis associated with meningioma: a case report. Acta Cytol. 2009 Jan-Feb; 53(1):93-7.
View in: PubMed

Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin Cancer Res. 2009 Jan 01; 15(1):330-7.
View in: PubMed

p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature. 2008 Oct 23; 455(7216):1129-33.
View in: PubMed

Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma. Cancer Cell. 2008 Aug 12; 14(2):123-34.
View in: PubMed

Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. Neuro Oncol. 2008 Jun; 10(3):300-8.
View in: PubMed

Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development. Cancer Cell. 2008 Apr; 13(4):355-64.
View in: PubMed

Myelin abnormalities without oligodendrocyte loss in periventricular leukomalacia. Brain Pathol. 2008 Apr; 18(2):153-63.
View in: PubMed

Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007 Nov 01; 21(21):2683-710.
View in: PubMed

Impaired human hippocampal neurogenesis after treatment for central nervous system malignancies. Ann Neurol. 2007 Nov; 62(5):515-20.
View in: PubMed

Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science. 2007 Oct 12; 318(5848):287-90.
View in: PubMed

Embryonic stem cell transcription factor signatures in the diagnosis of primary and metastatic germ cell tumors. Am J Surg Pathol. 2007 Jun; 31(6):836-45.
View in: PubMed

Expression of p16Ink4a compensates for p18Ink4c loss in cyclin-dependent kinase 4/6-dependent tumors and tissues. Cancer Res. 2007 May 15; 67(10):4732-41.
View in: PubMed

Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma. Neuron. 2007 Feb 15; 53(4):503-17.
View in: PubMed

Disruption of diacylglycerol kinase delta (DGKD) associated with seizures in humans and mice. Am J Hum Genet. 2007 Apr; 80(4):792-9.
View in: PubMed

Semiautomated multiplexed quantum dot-based in situ hybridization and spectral deconvolution. J Mol Diagn. 2007 Feb; 9(1):20-9.
View in: PubMed

Comparative analysis of germ cell transcription factors in CNS germinoma reveals diagnostic utility of NANOG. Am J Surg Pathol. 2006 Dec; 30(12):1613-8.
View in: PubMed

Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2. J Neuropathol Exp Neurol. 2006 Dec; 65(12):1149-56.
View in: PubMed

Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Res. 2006 Dec 01; 66(23):11502-13.
View in: PubMed

A novel somatic mouse model to survey tumorigenic potential applied to the Hedgehog pathway. Cancer Res. 2006 Oct 15; 66(20):10171-8.
View in: PubMed

p16INK4a induces an age-dependent decline in islet regenerative potential. Nature. 2006 Sep 28; 443(7110):453-7.
View in: PubMed

Olig gene function in CNS development and disease. Glia. 2006 Jul; 54(1):1-10.
View in: PubMed

Development of NG2 neural progenitor cells requires Olig gene function. Proc Natl Acad Sci U S A. 2006 May 16; 103(20):7853-8.
View in: PubMed

Evidence for motoneuron lineage-specific regulation of Olig2 in the vertebrate neural tube. Dev Biol. 2006 Apr 01; 292(1):152-64.
View in: PubMed

Histology-based expression profiling yields novel prognostic markers in human glioblastoma. J Neuropathol Exp Neurol. 2005 Nov; 64(11):948-55.
View in: PubMed

Diffusion-weighted imaging of fungal cerebral infection. AJNR Am J Neuroradiol. 2005 May; 26(5):1115-21.
View in: PubMed

Molecular diversity of astrocytes with implications for neurological disorders. Proc Natl Acad Sci U S A. 2004 Jun 01; 101(22):8384-9.
View in: PubMed

The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas. J Neuropathol Exp Neurol. 2004 May; 63(5):499-509.
View in: PubMed

Loss of Emx2 function leads to ectopic expression of Wnt1 in the developing telencephalon and cortical dysplasia. Development. 2003 May; 130(10):2275-87.
View in: PubMed

Arginase deficiency with lethal neonatal expression: evidence for the glutamine hypothesis of cerebral edema. J Pediatr. 2003 Mar; 142(3):349-52.
View in: PubMed

Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell. 2002 Apr; 1(3):269-77.
View in: PubMed

Cooperative transcriptional activation by the neurogenic basic helix-loop-helix protein MASH1 and members of the myocyte enhancer factor-2 (MEF2) family. J Biol Chem. 1996 Oct 25; 271(43):26659-63.
View in: PubMed

Scleraxis: a basic helix-loop-helix protein that prefigures skeletal formation during mouse embryogenesis. Development. 1995 Apr; 121(4):1099-110.
View in: PubMed

Paraxis: a basic helix-loop-helix protein expressed in paraxial mesoderm and developing somites. Dev Biol. 1995 Apr; 168(2):296-306.
View in: PubMed

Smooth muscle myosin heavy chain exclusively marks the smooth muscle lineage during mouse embryogenesis. Circ Res. 1994 Nov; 75(5):803-12.
View in: PubMed

Detection of p53 alterations in human astrocytomas using frozen tissue sections for the polymerase chain reaction. J Neurooncol. 1993 May; 16(2):125-33.
View in: PubMed

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Jimmy Fund 215B
Boston, MA 02215
Get Directions

Brigham and Women's Hospital
75 Francis Street
Boston, MA 02215
Get Directions

Top